BCRX
$9.70-0.11 (-1.12%)
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acu...
Recent News
BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Dominating Today’s Market Action. BioCryst grew its share prices by 7.10 percent on Thursday to close at $9.81 apiece as investors repositioned portfolios following rumors that it is set to be acquired by a large-cap US biopharmaceutical company. The report first broke out on Monday […]
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.’s share was trading at $9.30 as of March 16th. BCRX’s trailing and forward P/E were 7.69 and 109.89 respectively according to Yahoo Finance. BioCryst […]
BioCryst Takeover Rumors Test Investor Focus On Fundamentals And Optionality
Rumors of a potential acquisition of BioCryst Pharmaceuticals by a larger biopharmaceutical company have circulated widely in recent sessions. The company, listed as NasdaqGS:BCRX, has not issued any public comment on the speculation. These rumors come as BioCryst shares last closed at $9.16, with strong recent returns over the past month. For investors tracking NasdaqGS:BCRX, the timing of the acquisition chatter is important. The stock last closed at $9.16, with returns of 7.9% over the...
BioCryst (BCRX) Soars 13% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Worth Watching Right Now. BioCryst snapped a three-day losing streak on Monday, jumping 13.14 percent to finish at $9.30 apiece, as investors loaded portfolios amid rumors that it is set to be acquired by a large-cap biopharmaceutical company. Murmurs about the supposed acquisition broke out […]
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 2, Wedbush analyst Laura Chico increased the firm’s price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $22 from $21. The analyst maintained her Outperform rating on the stock. Although the company had previously preannounced […]